(-)-(S)-Equol
Based on 3 publication(s) in Google Scholar
(-)-(S)-Equol is a high affinity ligand for estrogen receptor β with a Ki of 0.73 nM.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.71%
- No. CAS: 531-95-3
- Fòrmula: C15H14O3
- Peso molecular:242.27
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-103456
PHTPPERβ Antagonist -
HY-108414
(R)-EquolEstrogen Receptor/ERR Agonist -
HY-N0377
LiquiritigeninEstrogen Receptor/ERR Agonist -
HY-100583R
(-)-(S)-Equol (Standard)Estrogen Receptor β Ligand -
HY-14933
PrinaberelERβ Agonist -
HY-N0019
DaidzeinEndogenous Metabolite -
HY-Y0320
Dimethyl sulfoxide, meets analytical specification of Ch.P.Aprotic Solvent -
HY-B0075
MelatoninMelatonin Receptor Activator -
HY-N4075
O-DesmethylangolensinEndogenous Metabolite -
HY-B1511
Cyclic AMPSecond Messenger -
HY-A0181
Adenosine monophosphateAdenosine A1 Receptor Agonist -
HY-N0018
DaidzinReverse Transcriptase Inhibitor
Publications Citing Use of MedChemExpress (MCE) (-)-(S)-Equol
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
Bio/Physico-chemical Assay
-
Flow Cytometry
-
WB
Ver todos los productos específicos de isoformas Endogenous Metabolite
More
Actividad biológica
Descripciòn
IC50 & Target
|
Human Endogenous Metabolite |
In Vitro
(-)-(S)-Equol shows the greatest affinity for ERβ (Ki=0.73±0.2 nM), whereas its affinity for ERα (Ki=6.41±1 nM) is relatively poor[1].
(-)-(S)-Equol inhibits the growth of LnCaP, DU145 and PC3 human prostate cancer cell lines. (-)-(S)-Equol causes cell cycle arrest in the G2/M phase in PC3 cells by down regulating cyclin B1 and CDK1 and upregulating CDK inhibitors (p21 and p27), as well as inducing apoptosis by upregulating Fas ligand (FasL) and the expression of pro-apoptotic Bim. (-)-(S)-Equol increases the expression of FOXO3a, decreases the expression of p-FOXO3a and enhances the nuclear stability of FOXO3a. (-)-(S)-Equol also decreases the expression of MDM2, which serves as an E3 ubiquitin ligase forp-FOXO3a, thus preventing p-FOXO3a degradation by the proteasome[2].
(-)-(S)-Equol enantioselectively increases the survival of INS-1 cells presumably through activating PKA signaling. (-)-(S)-Equol might have applications as an anti-type 2 diabetic agent. In INS-1 pancreatic β-cells, (-)-(S)-Equol induces phosphorylation of cAMP-response element-binding protein at Ser 133, and induced cAMP-response element-mediated transcription[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 531-95-3
-
Appearance Solid
-
Peso molecular 242.27
-
Fòrmula C15H14O3
-
Color White to yellow
-
SMILES
OC1=CC=C2C[C@H](COC2=C1)C3=CC=C(C=C3)O
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
NPJ Biofilms Microbiomes
Modulation of gut microbiota and its metabolite Equol by Huaier granule suppresses hepatocellular carcinoma via the gut-liver axis. [Abstract]2026 Jan 26;12(1):54. PMID: 41588026
(-)-(S)-Equol purchased from MedChemExpress. Usage Cited in: NPJ Biofilms Microbiomes. 2026 Jan 26;12(1):54. [Abstract]
(-)-(S)-Equol (S-equol; 0, 5, 10, 15, 20, 25 μM; 24, 48, 72 h) significantly reduced the proliferative capacity of human HCC HepG2 and Bel7402 cells concentration- and time-dependently.
(-)-(S)-Equol purchased from MedChemExpress. Usage Cited in: NPJ Biofilms Microbiomes. 2026 Jan 26;12(1):54. [Abstract]
(-)-(S)-Equol (S-equol; 0, 5, 10 μM; 8 days) significantly inhibited the colony-forming ability of HepG2 and Bel7402 cells.
(-)-(S)-Equol purchased from MedChemExpress. Usage Cited in: NPJ Biofilms Microbiomes. 2026 Jan 26;12(1):54. [Abstract]
(-)-(S)-Equol (S-equol; 0, 10, 20 μM; 24 h) significantly reduced ATP production of HepG2 and Bel7402 cells.
(-)-(S)-Equol purchased from MedChemExpress. Usage Cited in: NPJ Biofilms Microbiomes. 2026 Jan 26;12(1):54. [Abstract]
(-)-(S)-Equol (S-equol; 0, 10, 20 μM; 24 h) induced a G0/G1 phase arrest in human HCC HepG2 and Bel7402 cell.
(-)-(S)-Equol purchased from MedChemExpress. Usage Cited in: NPJ Biofilms Microbiomes. 2026 Jan 26;12(1):54. [Abstract]
(-)-(S)-Equol (S-equol; 0, 10, 20 μM; 48 h) downregulated the abundances of Cyclin E1, CDK2, and p-Rb proteins in HepG2 and Bel7402 cells.
(-)-(S)-Equol purchased from MedChemExpress. Usage Cited in: NPJ Biofilms Microbiomes. 2026 Jan 26;12(1):54. [Abstract]
(-)-(S)-Equol (S-equol; 10, 20, 40 mg/kg; once a day for 12 days, p.o.) significantly suppressed tumor development in orthotopic HCC model mice.
-
Int J Biol Macromol
Mechanism of dsDNA binding, enzyme inhibition, antioxidant activities, and molecular docking studies of taxifolin, daidzein, and S-equol. [Abstract]2025 Apr:300:140314. PMID: 39864700 -
Mol Cell Biochem
S-equol promotes ferroptosis in triple negative breast cancer by coordinating NCOA4-mediated ferritinophagy and PPARγ-mediated lipid metabolism. [Abstract]2026 May;481(5):2119-2137. PMID: 41925800
Solvente y solubilidad
In Vitro:
DMSO : 100 mg/mL (412.76 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (10.32 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (41.28 mM); Clear solution; Need ultrasonic
Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 5 mg/mL (20.64 mM); Clear solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (286 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Setchell KD, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9. [Content Brief]
[2]. Lu Z, et al. S-equol, a Secondary Metabolite of Natural Anticancer Isoflavone Daidzein, Inhibits Prostate Cancer Growth In Vitro and In Vivo, Though Activating the Akt/FOXO3a Pathway. Curr Cancer Drug Targets. 2016;16(5):455-65. [Content Brief]
[3]. Horiuchi H, et al. S-equol nantioselectively activates cAMP-protein kinase A signaling and reduces alloxan-induced cell death in INS-1 pancreatic β-cells. J Nutr Sci Vitaminol (Tokyo). 2014;60(4):291-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.1276 mL | 20.6381 mL | 41.2763 mL | 103.1907 mL |
| 5 mM | 0.8255 mL | 4.1276 mL | 8.2553 mL | 20.6381 mL | |
| 10 mM | 0.4128 mL | 2.0638 mL | 4.1276 mL | 10.3191 mL | |
| 15 mM | 0.2752 mL | 1.3759 mL | 2.7518 mL | 6.8794 mL | |
| 20 mM | 0.2064 mL | 1.0319 mL | 2.0638 mL | 5.1595 mL | |
| 25 mM | 0.1651 mL | 0.8255 mL | 1.6511 mL | 4.1276 mL | |
| 30 mM | 0.1376 mL | 0.6879 mL | 1.3759 mL | 3.4397 mL | |
| 40 mM | 0.1032 mL | 0.5160 mL | 1.0319 mL | 2.5798 mL | |
| 50 mM | 0.0826 mL | 0.4128 mL | 0.8255 mL | 2.0638 mL | |
| 60 mM | 0.0688 mL | 0.3440 mL | 0.6879 mL | 1.7198 mL | |
| 80 mM | 0.0516 mL | 0.2580 mL | 0.5160 mL | 1.2899 mL | |
| 100 mM | 0.0413 mL | 0.2064 mL | 0.4128 mL | 1.0319 mL |
(-)-(S)-Equol Related Classifications
HY-100583 Related Classifications
Powered by Bioz